- Remove this product from my favorite's list.
- Add this product to my list of favorites.
Products
Newsletter
Background: Protein kinase C (PKC) is a family of serine-threonine kinases, which are classified into three major groups: classical (α, β and γ), novel (δ, ε, η, and θ) and atypical (μ, ξ and ι). PKCβ2 consists of a C-terminal kinase domain and a N-terminal regulatory domain, formed by C1 domains (C1A and C1B) and a C2 domain. Activation of PKC beta 2 involves recruitment to the membrane and interaction with phospholipids, Ca2+ and diacylglycerol. Furthermore, fully active protein results upon phosphorylation of the activation loop. PKCβ is expressed in pancreatic islet cells, monocytes, brain, and many vascular tissues, including retina, kidney and heart and dysregulation is associated with pathogenic processes involved in diabetic microangiopathy such as ischaemia, leakage, neovascularisation and abnormal vasodilator function. The two isoforms, PKC beta 1 and PKC beta 2, are generated by alternative splicing from a single gene and differ at their C-terminus.
Purified human recombinant protein kinase C beta 2 (PKCβ2) containing amino acids 1-673, N-terminally fused to GST-Thrombin cleavage site
Theoretical MW (PKC-beta2): 103.7 kDa (fusion protein)
Expression system: Baculovirus infected Sf9 cells
Purification: One-step affinity purification using GSH-agarose
Storage buffer: 50 mM Tris-HCl, pH 8.0; 100 mM NaCl, 5 mM DTT, 15 mM reduced glutathione, 20% glycerol
Protein concentration: 0.145 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: Filter binding assay MAFC membrane
Specific activity: 320,000 pmol/mg x min
Entrez Gene ID: 5579
UniProtKB: P05771
Ordering information: shipped on dry ice
Tuttle KR. (2008) "Protein kinase C-beta inhibition for diabetic kidney disease." Diabetes Res Clin Pract. 13;82
Avignon A, Sultan A. (2006) "PKC-B inhibition: a new therapeutic approach for diabetic complications?" Diabetes Metab. 32(3):205-13.
Carroll MP, May WS (1994) "Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells" J Biol Chem 269(2):1249-56
Newton AC (1995) "Protein kinase C: structure, function, and regulation" J Biol Chem. 270(48):28495-8
Newton AC (1997) "Regulation of protein kinase C" Curr Opin Cell Biol. 9(2):161-7
Kawakami T, Kawakami Y, Kitaura J. (2002) " Protein kinase C beta (PKC beta): normal functions and diseases." J Biochem.;132 (5):677-82.
Idris I, Donnelly R. (2006) " Protein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy." Diab Vasc Dis Res.;3(3):172-8
Corbalán-García S, Gómez-Fernández JC. (2006) "Protein kinase C regulatory domains: the art of decoding many different signals in membranes." Biochim Biophys Acta. 1761(7):633-54.
Recombinant human Protein Kinase C (PKC) alpha, 10 µg - 465,00 €
PKC substrate, 1mg - 150,00 €
Recombinant human Protein kinase C (PKC) beta 1, 10 µg - 465,00 €
Recombinant human Protein kinase C (PKC) delta, 10 µg - 465,00 €
Recombinant human protein kinase C (PKC) theta, 10 µg - 465,00 €
Welcome Login
Contact us
Follow us